Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCT and C-CAR088 in Ultra High-risk Multiple Myeloma
NCT05632380Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2022
- Primary completion
- Sep 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of trovocabtagene autoleucel in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jul 2022; status: recruiting.
02
Drugs
trovocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05632380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05632380.